Vinpocetine - instructions for use, dose, side effects, contraindications

Excipients -Ascorbic acid 0.5 mg; D-sorbitol 80.0 mg; tartaric acid to pH 3.0-4.0; benzyl alcohol 10.0 mg; sodium disulfite 1.0 mg; water for injection up to 1 ml.

Description:Colorless or slightly colored solution.

Pharmacotherapeutic group:cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:

Vinpocetine selectively inhibits the potential-dependent sodium channels, causing a dose-dependent decrease in calcium concentration in the endings of neurons of the striatum. It is believed that a decrease in the sodium current has a neuroprotective effect due to a decrease in excitotoxicity and a weakening of neuronal damage caused by cerebral ischemia or reperfusion.

Vinpocetine increases the concentration of 3,4-dihydroxyphenylacetic acid (dopamine metabolite) in the nerve endings of the striatum. This action is similar to the pharmacological action of reserpine (reminiscent of the chemical structure vinpocetine), which depletes the supplies of catecholamines in the nerve endings of the brain, which causes side effects from the cardiovascular system and the antipsychotic effect.

It also inhibits phosphodiesterase 1, which leads to an increase in the concentration of intracellular cyclic guanosine monophosphate. This leads to a relaxation of the smooth muscles of the vessels of the brain.

Pharmacokinetics:

Therapeutic concentration in plasma with parenteral administration

- 10-20 ng / ml, the volume of distribution - 5.3 l / kg. The connection with plasma proteins is 66%, the clearance is -66.7 l / h, the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism. Penetrates into breast milk (0.25% within 1 hour), through the placental barrier. The half-life is 3.54 - 6.12. It is excreted by the kidneys and intestines in a ratio of 3: 2.

Indications:

Neurology (as part of complex therapy): as a symptomatic agent for variousforms of cerebral circulation failure (ischemic stroke, hemorrhagic stroke reducing step, the effects of stroke, transient ischemic attack, vascular dementia, circulatory insufficiency in the vertebrobasilar basin, cerebral atherosclerosis, traumatic and hypertensive encephalopathy);

Ophthalmology: chronic vascular and vascular disease of the retina (including occlusion of the central artery or retinal vein).

Decreased severity of perceptual hearing, Meniere's disease, idiopathic noises in the ears.

Contraindications:Hypersensitivity to the drug, the acute phase of hemorrhagic stroke, a severe form of coronary heart disease, severe heart rhythm disorders, pregnancy, lactation, age under 18 years (due to lack of data).

Dosing and Administration:

Intravenously drip (infusion rate should not exceed 80 cap / min).

The initial daily dose - 20 mg (diluted in 0.5 - 1l 0.9% sodium chloride or dextrose-containing solutions). The average daily dose at a body weight of 70 kg is 50 mg.With good tolerance for 2-3 days, the dose is raised to the maximum - 1 mg / kg / day. The course of treatment is 10-14 days.

After the termination of a course pass on oral reception of a preparation.

Precautions for use

Severe rhythm disturbances; with hemorrhagic stroke, the administration is possible only after the acute events subsided (usually in 5-7 days).

Side effects:

From the cardiovascular system: change on ECG (depression of ST segment, prolongation of Q-T interval); tachycardia, extrasystole (cause-and-effect relationship not established), lability of blood pressure (more often decrease).

From the central nervous system: sleep disturbances (insomnia, increased drowsiness), dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dry mouth, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia, phlebitis with intravenous administration.

Overdose:In case of an overdose, symptomatic treatment.

Interaction:

The solution of vinpocetine is pharmaceutically incompatible with heparin and solutions containing amino acids.

It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary).

Special instructions:

Effect on the ability to drive transp. cf. and fur:It is not recommended to use during the work of drivers of vehicles and people whose profession is associated with increased concentration of attention, since the drug may cause dizziness and other side effects that may affect these abilities.

Form release / dosage:Concentrate for solution preparation for infusions 5 mg / ml

Packaging:

5 ampoules per contour cell pack of polyvinyl chloride film.

2 contoured cell packs of polyvinylchloride film together with instructions for use and a scarifier ampoule or a knife ampoule in a pack of cardboard.

10 ampoules together with instructions for use and a scarifier ampoule or a knife ampoule in a pack of cardboard with a corrugated liner.

When using ampoules with a dot or a ring of fracture, a scarifier or ampoule knife is not inserted.

Storage conditions:Store in a dark place at a temperature of 15 ° C to 25 ° C. Keep out of the reach of children.

Shelf life:2 years.Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-001169

Date of registration:11.11.2011

The owner of the registration certificate:ELLARA, LTD. ELLARA, LTD. Russia

Manufacturer: & nbsp

MC ELLARA, LLC Russia

Representation: & nbspMC ELLARA LLC MC ELLARA LLC Russia

Information update date: & nbsp25.09.2015

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)